{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:11Z","timestamp":1753891991253,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Endometrial carcinoma is the most common gynecologic cancer, with increasing incidence and mortality. Combination endocrine therapy comprised of tamoxifen and progestational agents has demonstrated promising results in treating recurrent disease. This case report describes the prolonged clinical benefit of treatment with tamoxifen and megestrol acetate in a woman with recurrent, metastatic endometrial endometrioid carcinoma positive for estrogen (ER) and progesterone receptors (PR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Case<\/jats:title><jats:p>A 71-year-old gravida 1 para 1 woman presented with postmenopausal bleeding and vaginal discharge. Pelvic ultrasound and magnetic resonance imaging confirmed a 4.7 cm endometrial mass. The patient underwent a total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and cystoscopy; pathology revealed a FIGO stage IA grade 1 ER\/PR-positive endometroid endometrial adenocarcinoma. She continued under active surveillance for approximately 42 months until she experienced bone metastases in her pelvis, for which she received radiation therapy. Five months later, pulmonary metastases were detected, and she received six cycles of carboplatin and paclitaxel. She then started megestrol acetate and tamoxifen and has remained clinically stable with minimal side effects and reasonable quality of life for approximately 57 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our case suggests that combination endocrine therapy has the potential to provide substantial long-term clinical benefit in women with recurrent endometrial cancer and bone metastases, despite multiple prior treatments, allowing patients to experience stable disease and quality of life. In patients with recurrent endometrioid, ER\/PR-positive disease, endocrine therapy alone or in combination with other targeted therapies are regimens that may be considered due to their low overall toxicity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1249370","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:42:05Z","timestamp":1701067325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Joyce M.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna L.","family":"Beavis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tullia","family":"Rushton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182605bf1","article-title":"Endometrial cancer","volume":"120","author":"Sorosky","year":"2012","journal-title":"Obstet Gynecol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/cancers13246275","article-title":"Recurrent endometrial cancer: local and systemic treatment options","volume":"13","author":"R\u00fctten","year":"2021","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0091","article-title":"Treatment for advanced and recurrent endometrial carcinoma: combined modalities","volume":"15","author":"Rauh-Hain","year":"2010","journal-title":"Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00126-4","article-title":"Survival after relapse in patients with endometrial cancer: results from a randomized trial\u2606","volume":"89","author":"Creutzberg","year":"2003","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13471","article-title":"Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer","volume":"8","author":"Shen","year":"2016","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a\u00a0gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12957-015-0619-1","article-title":"Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2015","journal-title":"World J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","author":"Concin","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer:\u00a0ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"B18","article-title":"Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen","volume":"41","author":"Mortel","year":"1981","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_280495","article-title":"Therapeutic targets and opportunities in endometrial cancer: update on endocrine therapy and nonimmunotherapy targeted options","author":"MacKay","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00359","article-title":"Anti-estrogen treatment in endometrial cancer: A systematic review","volume":"9","author":"van Weelden","year":"2019","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1249370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:42:08Z","timestamp":1701067328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1249370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":20,"alternative-id":["10.3389\/fonc.2023.1249370"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1249370","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"article-number":"1249370"}}